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Abstract
TAR DNA-binding protein 43 (TDP-43) inclusions are pathological hallmarks of patients with frontotemporal lobar
degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Loss of TDP-43 in zebrafish engenders a severe muscle
and vascular phenotype with a concomitant elevation of filamin C (FLNC) levels, an observation confirmed in the
frontal cortex of FTLD-TDP patients. Here, we aimed to further assess the contribution of FLNC to frontotemporal
dementia (FTD) etiology. We conducted a mutational screening of FLNC in a cohort of 529 unrelated Belgian FTD
and FTD-ALS patients, and a control cohort of 920 unrelated and age-matched individuals. Additionally we performed
an in-depth characterization of FLNC expression levels in FTD patients and a murine FTD model.
In total 68 missense variants were identified of which 19 (MAF < 1 %) were patient-only. Gene burden analysis
demonstrated a significant association between the presence of rare variants in FLNC and disease (P = 0.0349, RR = 1.46
[95 % CI 1.03–2.07]). Furthermore, elevated FLNC expression levels, observed previously in FTLD-TDP patients, were
mainly attributable to FTD patients with the progranulin (GRN) p.0(IVS1 + 5G > C) loss-of-function mutation. Increased
FLNC levels were, to a lesser extent, also identified in a FLNC p.V831I variant carrier and in FTD patients with the
p.R159H mutation in valosin-containing protein (VCP). The GRN-associated increase of FLNC was confirmed in the
frontal cortex of aged Grn knockout mice starting at 16–18 months of age. Combined quantitative proteomic and
bioinformatic analyses of the frontal cortex of FTD patients possessing elevated FLNC levels, identified multiple altered
protein factors involved in accelerated aging, neurodegeneration and synaptogenesis.
Our findings further support the involvement of aberrant FLNC expression levels in FTD pathogenesis. Identification of
increased FLNC levels in aged Grn mice and impaired pathways related to aging and neurodegeneration, implies a
potential role for FLNC in mediating or accelerating the aging process.
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Introduction
Frontotemporal dementia (FTD) is a progressive presenile
dementia with degeneration of the frontal and anterior
temporal lobes of the brain [1]. The clinical phenotype of
FTD patients is heterogeneous and includes cognitive,
behavioral and language impairments with a variable
co-occurrence of amyotrophic lateral sclerosis (ALS)
[2]. Formation of insoluble protein deposits, largely com-
posed of ubiquitinated, hyperphosphorylated TAR DNA-
binding protein 43 (TDP-43), defines one of the major
pathological subtypes of frontotemporal lobar degeneration
(FTLD-TDP) as well as ALS patients, introducing a clinico-
pathological continuum of TDP-43 proteinopathies [3–5].
TDP-43 is a multifunctional RNA-binding protein involved
in different RNA-related processes including transcription
and splicing regulation [6, 7].
Over the past ten years, considerable progress has been
made in unraveling the genetic basis of the FTD-ALS
continuum. Today, more than 10 genes are linked to
FTD-ALS disorders at variable frequencies [8, 9]. A major
part of the mutation spectrum described for FTLD-TDP
patients is covered by loss-of-function mutations in pro-
granulin (GRN) that codes for a multifunctional growth
factor with neurotrophic properties in the central nervous
system (CNS) [10] and a hexanucleotide repeat expansion
mutation in C9orf72 [11]. Less frequently, mutations in
TANK-binding kinase 1 (TBK1), TAR DNA-binding
protein 43 (TARDBP), valosin-containing protein (VCP),
sequestosome 1 (SQSTM1) and ubiquilin 2 (UBQLN2)
can lead to both familial and sporadic forms of FTD and
ALS [8].
The high prevalence of TDP-43 pathology in FTD and
ALS patients suggests that pathways disrupting TDP-43
integrity might be shared between patients with different
clinical, pathological and genetic etiologies. In line with
the molecular genetic findings, multiple pathways related
to RNA-processing, protein aggregation and proteosta-
sis are likely contributing to the multifactorial nature of
FTD-ALS disorders [9]. Recently, an unexpected require-
ment of TDP-43 for muscle maintenance, vessel pattern-
ing and perfusion was found upon deletion of the TDP-43
homologues in zebrafish [12]. Several muscle-specific pro-
teins were altered on proteomic analysis of this zebrafish
model, underscoring the role of TDP-43 in muscle integ-
rity. The most upregulated protein in TDP-43 knockout
zebrafish and in the frontal cortex of FTLD-TDP patients,
however, was filamin C (FLNC) [12]. Filamins are evolu-
tionary conserved, multidomain actin-binding proteins
involved in the organization of the cytoskeleton and
plasma membrane stabilization. Besides cross-linking
F-actin filaments, filamins scaffold also a wide range of
signaling functions through interactions with more than
90 binding partners including intracellular signaling
molecules, transmembrane receptors, and ion channels
[13, 14]. The vertebrate filamin family consists of fila-
min A (FLNA), filamin B (FLNB) and filamin C (FLNC)
which share ≈ 70 % homology over the entire protein
sequence. Structurally, FLNC is a large homodimer of
approximately 290-kDa subunits that consists of an N-
terminal actin-binding domain (ABD), composed of two
calponin homology domains (CH1 and CH2), followed by
24 Immunoglobulin (Ig)-like repeats [15–17]. Two splice
variants have been described for FLNC which differ from
each other in the presence of exon 31 encoding the hinge
region between Ig-like domains 15 and 16 (Fig. 1a). FLNC
expression is largely restricted to cardiac and skeletal
muscles, although other non-muscular cells, including
neuronal cells, express lower but detectable levels of FLNC
[18–20]. In line with the expression pattern of FLNC,
mutations identified in FLNC have been shown to be
the underlying cause of different progressive muscular
dystrophies, including distal and myofibrillar myopathy
(DM and MFM, respectively), and hypertrophic cardio-
myopathy (HCM) [21–23].
In the present study, we showed that rare variants
(MAF < 1 %) identified in the coding region of FLNC are
significantly associated with a higher risk of developing
FTD. We also performed an in-depth characterization of
FLNC transcript and protein levels in FTD patients with
different genetic etiologies and found that elevated FLNC
levels observed in the frontal cortex of FTLD-TDP pa-
tients are mainly associated with the GRN p.0(IVS1 +
5G > C) loss-of-function mutation. Validation of this
novel association was obtained using a constitutive Grn
knockout (Grn−/−) mouse model [24]. To appreciate the
pathophysiological relevance of increased FLNC levels, we
analyzed the frontal cortex of FTD patients with different
genetic etiologies for significantly altered gene-specific
pathways using combined proteomic and bioinformatic
approaches.
Materials and methods
Belgian FTD and control cohorts
The FTD patients and control cohorts were ascertained
in the framework of the Belgian Neurology (BELNEU)
consortium, a multicenter collaboration of dementia ex-
pertise centers located in Belgium, covering Flanders,
Wallonia and Brussels [25]. Molecular genetic screening
of FLNC was performed on 529 FTD patients with an
average age at onset of 63.8 ± 10.3 years (45.5 % women).
Index patients were evaluated and diagnosed according
to standard protocols including detailed neurological
examination, neuropsychological testing, neuroimaging,
biochemical analyses, and electroencephalography (EEG)
[26]. Clinical diagnosis of FTD was reached according to
the international Lund and Manchester group criteria for
FTD [1] and the international consensus criteria by
Rascovsky et al. [27] for behavioral variant FTD (bvFTD).
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Post mortem neuropathological diagnosis of FTLD was
available in 33 patients (6.2 %), including 3 FTD-ALS
patients, 1 patient with mixed dementia and 25 FTD
patients. A positive family history, i.e. at least one first
degree relative with a FTD-ALS spectrum disease, was
recorded for 30.4 % of the FTD cohort, while 33.8 %
had a sporadic form of the disease. Familial history was
unknown for 35.2 % of the patients included in this co-
hort. FTD patients included in this cohort had previously
been screened for mutations in known FTD and ALS
genes including MAPT, GRN, C9orf72, VCP, CHMP2B,
TARDBP, FUS, and SQSTM1 [9], which revealed 5 MAPT
mutations (0.9 %), 28 GRN mutations (5.3 %), 35 C9orf72
repeat expansion mutations (6.6 %), 6 VCP mutations
(1.1 %), 1 CHMP2B mutation (0.2 %), 2 TARDBP muta-
tions (0.4 %), 3 FUS mutations (0.6 %), and 10 SQSTM1
mutations (1.9 %).
The control cohort consisted of 920 unrelated and
age-matched individuals, primarily community-dwelling
volunteers or spouses of patients, with an average age at
inclusion of 68.0 ± 13.2 years (60.8 % women). Subjective
memory complaints, neurologic or psychiatric antecedents
and a familial history of neurodegeneration were ruled out
by means of an interview. Cognitive screening was per-
formed using the Mini-Mental State Examination (MMSE;
cut-off score ≥26) [28] or the Montreal Cognitive Assess-
ment (MoCA) test (cut-off score >25) [29]. The spouses of
patients were examined at the Memory Clinic at Middel-
heim or Hoge Beuken hospitals of the Hospital Network
Antwerp, Belgium, and at the Memory Clinic of the
hospital Gasthuisberg of the University Hospitals of
Leuven, Belgium.
All research participants or their legal guardian provided
written informed consent for participation in genetic and
clinical studies. Clinical study protocols and informed
consent forms for patient ascertainment were approved by
the local medical ethics committees of the collaborating
neurological centers in Belgium. Genetic study protocols
and informed consent forms were approved by the ethics
committees of the University Hospital of Antwerp and the
University of Antwerp, Belgium.
FLNC sequencing
The coding sequence of FLNC, including flanking intron-
exon boundaries, was screened in the Belgian FTD and
control cohorts using a massive parallel sequencing
approach and a customized Multiplex Amplification of
Specific Targets for Resequencing (MASTR) assay
(Multiplicom; www.multiplicom.com). Exons 46-48 of
FLNC were not covered in the MASTR assay due to more
than 98 % sequence identity with the FLNC pseudogene
(pseFLNC), located 53.6 kb downstream of the functional
FLNC gene [30]. Primers for multiplex PCR were designed
using the mPCR primer design tool (Multiplicom) [31].
Specific target regions were amplified using multiplex
PCR, and equimolar pooled amplicons were purified using
Agencourt AMPureXP beads (Beckman Coulter). Indi-
vidual barcodes (Illumina Nextera XT) were incorporated
Fig. 1 FLNC variants identified in patients of the Belgian FTD cohort. a Schematic representation of the short and long isoform of FLNC, which differ
from each other in the presence or absence of one exon (marked in red). b 19 FLNC variants identified in patients of the Belgian FTD cohort (marked
in red) mapped on the domain structures of the FLNC gene. Represented variants were absent from 920 control individuals. Immunoglobulin (Ig)-like
domains are numbered from 1 to 24. CH1 and CH2: calponin homology domains. Assignment of FLNC variants to the corresponding domain structure
was based on the UniProt database (http://www.uniprot.org/)
Janssens et al. Acta Neuropathologica Communications  (2015) 3:68 Page 3 of 18
in a universal PCR step prior to sample pooling. Bridge
amplification and sequencing of barcoded samples was
performed using an Illumina MiSeq platform, with the
Illumina v2 reagent kit.
Alignment and mapping of the reads against the human
genome reference sequence hg19 were performed with
the Burrows-Wheeler Aligner [32]. Variant calling and
annotation were performed using GATK (version 2.2)
in combination with GenomeComb software [33, 34].
Identified variants were independently validated using
direct Sanger sequencing on genomic DNA. FLNC codon
numbering was based on GenBank Accession Number
NM_001458.4 and amino acid substitutions are numbered
according to GenPept Accession Number NP_001449.3
(http://www.ncbi.nlm.nih.gov/).
The potential pathogenecity of patient-only coding vari-
ants were predicted using SIFT (http://sift.jcvi.org/) [35],
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) [36]
and SNAP2 (https://www.rostlab.org/services/SNAP/) [37]
prediction software tools.
Human and murine brain tissue
Human frontal cortex (BA10) was snap frozen in liquid
nitrogen upon autopsy and stored at −80 °C for subse-
quent mRNA and protein analyses. FLNC expression
levels were analyzed in brain tissue from 23 dementia pa-
tients including 1 FLNC p.V831I carrier, 7 carriers of a
GRN loss-of-function mutation [10], 3 carriers of the VCP
p.R159H mutation [38], 3 carriers of a C9orf72 repeat ex-
pansion [11], 4 patients with FTLD-TDP brain pathology
but no mutation in any of the known causal FTD genes,
and 1 patient with a mixed Alzheimer’s disease (AD) and
FTLD-TDP brain pathology. In addition, we analyzed
brain expression levels in 2 patients with AD, one patient
with dementia with Lewy Bodies (LBD) and one Down
syndrome patient, as well as in twelve age-matched con-
trol persons. A detailed overview of the patients with aut-
opsy and neuropathological examination is provided in
Table 1. A partial overlap in patients is present with sam-
ples included in the FLNC expression studies of Schmid
et al. 2012 [26]; i.e. control individuals (n = 12), 5 FTD
Table 1 Pathological and clinical characteristics of FTD, AD and DLB patients used in FLNC brain expression studies
DR number Gender Age at onset
(years)
Age at death
(years)
Family
History
Clinical diagnosis Mutation Pathological diagnosis
DR287.1 F 65 71 F FTD GRN - p.A89Vfsa41 FTLD-TDP type A
DR2.3a F 63 71 F FTD GRN - p.0(IVS1 + 5G > C) FTLD-TDP type A
DR8.1 F 62 68 F FTD GRN - p.0(IVS1 + 5G > C) FTLD-TDP type A
DR25.5a M 70 73 F FTD GRN - p.0(IVS1 + 5G > C) FTLD-TDP type A
DR27.1 F 58 63 F FTD GRN - p.0(IVS1 + 5G > C) FTLD-TDP
DR28.1 M 56 62 F FTD GRN - p.0(IVS1 + 5G > C) FTLD-TDP type A
DR25.1 F 69 75 F FTD GRN - p.0(IVS1 + 5G > C) FTLD-TDP type A
DR40.1 F 44 56 F FTD VCP - p.R159H FTLD-TDP type D
DR40.7 M 49 57 F FTD VCP - p.R159H FTLD-TDP
DR7.4 M 63 68 F FTD VCP - p.R159H FTLD-U
ADR1 M 52 62 F FTD FLNC - p.V831I Pick’s disease
DR439.1 M 54 69 F FTD C9Orf72 - G4C2 expansion FTLD-TDP type B
DR29.1a F 50 55 F FTD C9Orf72 - G4C2 expansion FTLD-UPS
DR14.1a M 56 60 F FTD C9Orf72 - G4C2 expansion FTLD-TDP type B
DR386.1 M 72 83 S MXD unknown FTLD-TDP and AD
DR189.1 M 47 50 F FTD unknown FTLD-TDP type B
DR87.1 F 79 88 S FTD unknown FTLD TDP
DR864.1 M 59 62 S FTD - ALS unknown FTLD-TDP type B
DR102.1a F 72 79 S FTD unknown FTLD-TDP
DR246.1a M 62 72 F DLB unknown LBD
DR865.1 M 75 86 U AD unknown AD (III-IV Braak)
DR39.1a F 61 75 F AD APP - c.-369C/G AD-CAA
DS1.1a - - - S Down Syndrome 47XX,+21 or 47XY,+21 AD-CAA
AD Alzheimer’s disease, APP amyloid precursor protein, CAA cerebral amyloid angiopathy, DLB dementia with Lewy bodies, UPS ubiquitin proteasome, system, DLBD
diffuse Lewy body disease, F familial; S sporadic, U unknown, MXD mixed dementia, VCP valosin-containing protein
Samples labeled with a were previously analyzed in FLNC expression studies published by Schmid et al. 2012 [12]
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patients (2 GRN p.0(IVS1 + 5G > C) carriers, 2 C9orf72
repeat expansion carriers, 1 FTLD-TDP patient without
known genetic cause, 2 AD patients and 1 LBD patient
(FTD patient samples used in both studies are indicated
with a "symbol a" in Table 1).
Human FLNC expression profiles obtained from FTD
patients were validated using a progranulin knockout
(Grn-/-) mouse model for FTD [24]. Mouse whole brain
tissue was harvested at different ages, weighed and cut
midsagittal according to a standard protocol [39]. Right
hemispheres were snap frozen in liquid nitrogen and
stored at −80 °C for subsequent mRNA and protein ana-
lysis. Left hemispheres were fixed in 2 % paraformaldehyde
(PFA) for 18–20 h and prepared for paraffin embedding.
RNA extraction for semi-quantitative real-time PCR
Semi-quantitative real-time PCR (qRT-PCR) was performed
to quantify expression levels of FLNC in the human frontal
cortex and mouse right hemisphere. Total RNA was
isolated from crunched frozen brain tissue using the
RiboPure™ RNA Purification kit followed by a DNase
treatment with the TURBO™ DNase kit (both Ambion,
Life Technologies). The RNA integrity values (RIN) of pa-
tient and control samples ranged between 5 and 8.4. First-
strand cDNA was synthesized utilizing the SuperScript®
III First-Strand Synthesis System (Life Technologies) with
random hexamer primers. qRT-PCR reactions were
performed using the Fast SYBR® Green mix and run on
an ABI ViiA™ 7 Real-Time PCR System (both Applied
Biosystems, Life Technologies). Each sample was mea-
sured in duplicate and at least two independent experi-
ments were performed. Quantification of mRNA levels
was achieved with glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) and β-Actin (ACTB) as internal control
genes. Normalization of the housekeeping genes was per-
formed using geometric averaging of the expression levels,
as described by Vandesompele et al. [40]. Primer pairs
were designed using Primer Express software (Life Tech-
nologies). Primer sequences are available upon request.
Immunoblotting
Protein extractions of human and murine brains were
prepared in modified radioimmuno-precipitation (RIPA)
buffer [150 mM NaCl, 0.5 % sodium deoxycholate, 1 %
NP-40, 50 mM Tris–HCl; pH 8.0] supplemented with
1 % sodium dodecyl sulfate (SDS), as described previ-
ously [41]. Buffers were supplemented with protease and
phosphatase inhibitors (1x Complete Protease inhibitor
cocktail and 1x PhosSTOP, both Roche). Protein concen-
trations were determined with a Pierce™ bicinchoninic
acid (BCA) colorimetric protein assay kit (Thermo Scien-
tific). Equal amounts of protein were loaded and separated
on 3–8 % NuPAGE® Tris-Acetate or 4–12 % NuPAGE®
Bis-Tris gels (Life Technologies) and electrotransferred
onto a polyvinylidene difluoride membrane (PVDF,
Hybond P; Amersham Biosciences). After protein transfer,
membranes were blocked in 5 % skimmed milk in
phosphate-buffered saline (PBS) containing 0.1 % Tween®
20 (Merck). Membranes were probed with a range of
primary antibodies listed in Additional file 1: Table S1.
Immunodetection was performed with host-specific
secondary antibodies conjugated with horseradish per-
oxidase (HRP) and the ECL-plus chemiluminescent de-
tection system (Thermo Scientific). Western blot results
were visualized using the ImageQuant™ LAS4000 digital
imaging system and quantified with ImageQuant™ TL
software (GE Healthcare Life Sciences). Quantitative data
were normalized to GAPDH expression levels, as described
earlier [39].
Cell culture
Human cervical carcinoma cells (HeLa; CCL-2; ATCC)
were grown in Minimum Essential Medium Eagle (MEM,
Life Technologies) supplemented with 10 % fetal calf serum
(FCS, Life Technologies) and 500 U/500 μg penicillin/
streptavidin. Human neuroblastoma (KELLY) cells (Sigma)
were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM, Life Technologies) supplemented with 10 %
FCS, 2 mM L-Glutamine and 500 U/500 μg penicillin/
streptavidin. Cells were propagated in a humidified in-
cubator at 37 °C and 5 % CO2.
RNA interference
GRN expression was silenced in HeLa and KELLY cells
using three independent gene-specific siRNAs (Ambion,
Life Technologies). A non-targeting control siRNA with
scrambled sequences (Qiagen) and a negative control
(only transfection reagent) were included for each siRNA
experiment (sequences are listed in Additional file 1:
Table S2). Cells were transiently transfected with 20 nM
of gene-specific or scrambled siRNA using siLentFect™
transfection reagent (Bio-Rad) according to the manu-
facturer’s recommendations. Cellular RNA and protein
extractions were prepared 48 h post transfection ac-
cording to standard protocols [41]. Briefly, cells were
washed twice in ice-cold PBS and lysed in RIPA 1 %
SDS buffer supplemented with protease and phosphat-
ase inhibitors (1x Complete Protease inhibitor cocktail
and 1x PhosSTOP, both Roche). Lysates were sonicated
on ice, clarified by centrifugation at 14,000 rpm and
supernatant was used for subsequent immunoblotting
experiments.
Sample preparation for iTRAQ labeling and mass
spectrometry analysis
Human frontal cortex of 5 patients, including 2 FTD
carriers of GRN p.0(IVS1 + 5G > C) (DR8.1 and DR2.3),
2 FTD carriers of VCP p.R159H (DR40.1 and DR40.7), 1
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FLNC p.V831I carrier (ADR1) (Table 1), and of 3 control
individuals, were extracted using the Qproteome Cell
Compartment kit (Qiagen). Proteins extracted from the
cytoplasmic compartment using Qproteome were used
for subsequent mass spectrometry analyses. Following
acetone precipitation of the cytoplasmic protein extracts,
protein lysate concentrations were measured using the
RC DCTM protein assay (Bio-Rad Laboratories Inc.). A
total protein concentration of 100 μg from each sample
was reduced with tris(2-carboxyethyl)phosphine (TCEP)
and cysteine residues were blocked using the cysteine-
alkylation reagent methyl methanethiosulfonate (MMTS).
Next, samples were digested with sequencing-grade
trypsin (Promega) and peptides were used for isobaric
iTRAQ-8plex (isobaric mass-tag labeling for relative and
absolute quantification; iTRAQ [42]) mass tag labeling,
i.e. 113, 114, 115, 116, 117, 118, 119 or 121 labels, ac-
cording to the manufacturer’s protocol (Applied Biosys-
tems). Controls and patients samples were labeled for
1 h at room temperature with isobaric reagents as
follows: 3 control individuals (labels 113-115); 2 GRN
p.0(IVS1 + 5G > C) carriers (labels 117-118), 2 VCP
p.R159H carriers (labels 119-121) and a FLNC p.V831I
carrier (label 116). Following labeling, the tagged pep-
tides were pooled in equal volume ratios into one sam-
ple mix.
Labeled peptides were separated and resolved in two
dimensions, first by strong cation exchange (SCX) chro-
matography followed by nano-reversed phase (RP, C18)
chromatography on a 2D nano liquid chromatography (LC)
system (Ultimate 3000 RSL, Dionex, Thermo Scientific).
The nano-LC system was connected online to a Thermo
Fisher Q Exactive™ Plus Orbitrap Mass Spectrometer (MS)
system (Thermo Scientific).
Data-dependent acquisition (DDA) was obtained with
a full MS scan and a subsequent data dependent MS2
(ddMS2) scan. The full MS scan had a resolving power
of 70,000 and a scan range from 350 to 1500 m/z. The
top 10 precursor ions were selected for ddMS2 higher-
energy collisional dissociation (HCD) fragmentation with
a resolution of 17,500.
Data analysis, including identification and quantification
of labeled peptides, was performed using the Proteome
Discoverer software (v2.0, Thermo Scientific). Protein
identification was performed using the most recently
updated human UniProt/SwissProt database. Raw peptide
identification was done using workflow settings for the
Sequest HT search engine including a 10 ppm precursor
mass tolerance, 0.02 Da fragment mass tolerance, and
tolerance of maximum two missed trypsin cleavage
sites. Only peptide spectrum matches (PSM) that con-
tained all eight reporter ion channels were considered
for quantification and reporter intensities were exported
for further analysis.
Bioinformatic analyses of mass spectrometry data
Proteomic datasets generated from the Proteome Dis-
coverer v2.0 software were analyzed using a multidimen-
sional bioinformatic approach. The primary ratiometric
iTRAQ data was processed and normalized by perform-
ing a log2 transformation on the signal ratios retrieved
from the quantitative MS. Proteins demonstrating sig-
nificant deviation limits outside plus or minus 2 stand-
ard deviations (SD; 95 % confidence limits) from the
mean protein expression levels (based on normalized
background analysis) were used for further analysis.
To facilitate the specific separation of complex datasets,
and more specifically the significantly-regulated proteins,
originating from either the FLNC, GRN or VCP mutation
carriers (compared to control individuals), we employed
the novel Venn diagram platform, VennPlex [43]. Our
primary analyses were focused on significantly-
regulated protein subsets containing proteins common
to FLNC, GRN, and VCP carriers (FTD-common), but
also protein subsets specific and unique to FLNC, GRN
or VCP carriers. Classical functional annotation of these
protein subsets was performed with Gene Ontology
annotation (GO; http://geneontology.org/) and Kyoto
Encyclopedia of Genes and Genomes pathway analysis
(KEGG; http://www.genome.jp/kegg/) using the NIH DA-
VID Bioinformatics Resources 6.7 suite [44]. For both GO
term annotation (biological process only) and KEGG
pathway analyses we employed a cut-off of at least two
proteins needing to be present to fully populate a par-
ticular GO term group or KEGG pathway with a prob-
ability of enrichment value of P ≤0.05. A hybrid score
was employed to generate a single index for a specific-
ally enriched GO term group or KEGG pathway. Hybrid
scores are generated by the multiplication of the negative
log10 of enrichment probability with the enrichment factor
and the number of proteins populating the specific GO
term group or KEGG pathway.
Biomedical natural language processing (NLP) text analysis
was performed on the common and unique significantly-
regulated protein datasets using Textrous! [45, 46]. Textrous!
utilizes NLP techniques, including latent semantic
indexing (LSI), sentence splitting, word tokenization, parts-
of-speech tagging, and noun-phrase chunking, to mine the
MEDLINE-database (NCBI, http://www.ncbi.nlm.nih.gov/),
PubMed Central articles (NCBI, http://www.ncbi.nlm.nih.
gov/), the Online Mendelian Inheritance in Man catalog
(OMIM®, http://www.omim.org/), and the Mammalian
Phenotype Browser obtained from The Jackson Laboratory
(http://www.informatics.jax.org/searches/MP_form.shtml).
Textrous! has the ability to generate output data even with
very small input datasets for the selection, ranking,
clustering, and visualization of English words obtained
from the input user data. Significant data word clouds
were created from Textrous!-based semantic noun and
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noun-phrase outputs using the web-based application
Wordle (http://www.wordle.net/) [45]. The text size of
the word clouds is directly proportional to the input word
frequency. Analyses of word frequencies from Textrous!
noun-phrase outputs were made using WriteWords
(http://www.writewords.org.uk/word_count.asp).
LSI analysis was performed using GeneIndexer (Com-
putable Genomix), as described previously [47, 48]. In
brief, GeneIndexer correlates the strength of association,
using LSI, between specific proteins in a dataset with
user-defined interrogation text terms. GeneIndexer em-
ploys a comprehensive human or murine scientific text
database of ≥2 × 106 scientific abstracts to perform this
text-protein correlation analysis. The possible LSI cosine
similarity correlation scores for a gene to be associated
with an input interrogation term range from 0 to 1, with
the stronger correlation scores approaching 1. A correl-
ation score of ≥0.1 indicates at least an implicit correl-
ation, between the specific gene and the user-defined
input interrogation term.
Statistical analyses
We determined rare, low frequency and frequent variants
as genetic variants with a minor allele frequency (MAF)
below 1 %; between 1-5 % and above 5 %, respectively.
Rare variant gene burden analysis was performed by col-
lapsing rare alleles and comparing the overall frequency of
rare variant alleles between patients and control groups
using chi-squared (χ2) statistics. For two controls, more
than one FLNC variant was identified in the CDS and
these variants were counted as one mutated allele as no
relatives were available for phase determination of the var-
iants. The odds ratio (OR) and 95 % confidence intervals
(CI) were calculated as well. A two-sided p-value P <0.05
was considered as significant.
Expression studies were performed in duplicate and
repeated at least two times with results reported as
mean ± standard deviation (SD). P values for description
of statistical significance of differences were calculated
by Mann–Whitney U testing using the GraphPad Prism
5 Software. Values were considered to be significant if
*P < 0.05, **P < 0.01 or ***P <0.001.
Results
Identification of rare FLNC variants in Belgian FTD patients
We sequenced the coding sequence (CDS) of FLNC in
the Belgian FTD (n = 529) and control (n = 920) cohorts
and identified a total of 68 different genetic variants that
affected the coding sequence of FLNC. We observed 19
missense variants (MAF <1 %) in 21 patients, which
were absent from control individuals (Fig. 1b, Table 2).
The clinical diagnosis of the FLNC carriers was predom-
inantly FTD, except for the 2 patients with p.D710N and
p.T2025I, who were diagnosed with FTD-ALS and
corticobasal syndrome (CBS) (Table 2). Eight carriers
had a positive family history of disease, but their families
lacked information preventing co-segregation analysis
with disease. The patient-only variants were found across
the actin binding domain and different Immunoglobin
(Ig)-like domains of FLNC without indications of cluster-
ing in specific functional domains (Fig. 1b, Table 2). Com-
parative genomics analysis indicated that the majority of
FLNC variants predicted substitution of evolutionary con-
served amino acid residues in FLNC (Additional file 2:
Figure S1). For 5 FLNC variant carriers with FTD, another
genetic causal or risk variant had previously been identi-
fied (Table 2), 2 with a C9orf72 repeat expansion, 2 with a
GRN loss-of-function mutation and 1 with the TREM2
p.R47H risk allele (Table 2).
In addition to patient-only variants, we identified an-
other 15 missense FLNC variants that were present in
both FTD patients and control individuals. Except for
p.R1241C and p.R1567Q (MAF >1 % and >5 %), the other
13 were rare (MAF <1 %) (Additional file 1: Table S3a
and b). We also identified 34 missense variants present
only in control individuals (MAF <1 %) (Additional file 1:
Table S4). Three different prediction software programs,
i.e. SIFT, Polyphen-2 and SNAP2, were applied to estimate
the predicted pathogenicity of variants identified in FTD
patients and/or controls. However, the vast majority of
FLNC variants found in patients and/or controls were
predicted to have non-neutral effects (Additional file 1:
Table S5a-c).
Two control individuals were carrying 2 and 3 different
missense variants in FLNC. Interestingly, the p.A2430V
variant found in one control individual was previously
described in patients with hypertrophic cardiomyopathy
(HCM) [21].
Rare variant gene burden analysis in the Belgian FTD cohort
We performed a gene burden analysis collapsing all rare
variants with an MAF <1 % across the whole protein
and comparing the overall frequency of rare variant al-
leles between patients and controls using χ2 statistics.
Considering all rare variants observed in patients, we
obtained an overall cumulative frequency of 11.3 % (60/
529) compared to 7.9 % in control individuals (73/920).
The increased frequency in patients was significant with
an odds ratio of 1.46 (chi-squared (χ2) test, P = 0.0349;
95 % confidence interval (CI) = 1.03–2.07).
Increase of FLNC in FTLD-TDP patients is strongly linked
to GRN haploinsufficiency
In the initial report, published by Schmid et al. [12], the
expression levels of both the short and long isoforms of
human FLNC were found to be elevated in the frontal
cortex of FTLD-TDP patients, compared to neurologically
healthy control individuals and AD patients [12]. We
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analyzed FLNC expression levels in the frontal cortex
(BA10) of FTLD-TDP patients carrying a pathological
mutation in VCP, GRN or C9orf72 (Table 1), and of
FTLD-TDP patients without a known genetic cause
(nonmutation FTLD-TDP patients). Compared to tran-
script levels measured in the frontal cortex of control
individuals and of AD or DLB patients, both the short
and long isoform of FLNC were elevated up to 8.9 and
7.2 times in GRN p.0(IVS1 + 5G > C) carriers (Fig. 2a).
The long isoform of FLNC was also increased in non-
mutation FTLD-TDP patients (Fig. 2a). No altered ex-
pression patterns were observed in patients with the
VCP p.R159H or C9orf72 repeat expansion mutation.
Western blot analysis, using an antibody raised against
the carboxyl terminus of human FLNC confirmed the el-
evated expression of FLNC in GRN p.0(IVS1 + 5G > C)
patients compared to age-matched control individuals
(Fig. 2b). No notable increase could be observed for the
p.A89Vfs*41 frameshift mutation in FLNC expression. In
contrast to the transcript data, FLNC protein levels were
also elevated to a lower extent in FTD patients carrying
the VCP p.R159H mutation. No increased FLNC levels
were observed in a VCP carrier (DR7.4) that also carried
the FLNC low frequency variant p.R1241C (Additional
file 1: Table S3b). Interestingly, analysis of the FLNC
p.V831I carrier showed an increase in FLNC levels
compared to control individuals (Fig. 2b). Absence of
elevated FLNC levels in brains of AD patients was in
line with the transcript data and the previous data pub-
lished by Schmid et al. [12] (Fig. 2a and Additional file
2: Figure S2a). As the strongest alterations in FLNC ex-
pression were observed in FTD patients with GRN hap-
loinsufficiency, we verified whether reduced GRN levels
in vitro could confirm the FLNC increase seen in patients.
No significant changes, however, could be observed in
FLNC expression levels upon GRN knockdown in both
HeLa or KELLY cells (Additional file 2: Figure S3a-c).
Besides its anchoring and crosslinking functions, FLNC
is known to scaffold a wide range of signaling pathways
through interactions with signal transduction molecules,
receptors and ion channels. FLNC is phosphorylated by
protein kinase B-α at serine 2213 (pSer2213) and harbors
also a potential cAMP-dependent protein kinase A (PKA)
phosphorylation site at serine 2113 (pSer2113) [49].
Western blot analysis of the FLNC phosphorylation status
at these reported residues demonstrated a considerable
Table 2 Rare FLNC missense variations identified in Belgian FTD patients
Patient Variant Functional
domain
Gender Clinical diagnosis Sub-diagnosis Family
History
Age at onset
(years)
dbSNP Mutation in
known gene
DR554.1 p.R81C CH1 F FTD bvFTD F 56 - GRN p.W304
DR1221.1 p.E309K Ig 1 M FTD PNFA S 45 -
DR1222.1 p.E323V Ig 1 M FTD bvFTD S 71 -
DR659.1 p.K524R Ig 3 M FTD bvFTD F 38 - C9orf72 G4C2 exp.
DR454.1 p.D710N Ig 5 F FTD-ALS FTD - ALS F 69 rs370035829 C9orf72 G4C2 exp.
DR1223.1 p.A806T Ig 6 F FTD PSP F 63 -
ADR1 p.V831I Ig 6 M FTD bvFTD F 52 -
DR1224.1 p.V1047L Ig 8 F FTD - S 57 -
AD1485.1 p.P1163R Ig 10 M FTD bvFTD F 76 -
AD1430.1 p.V1335M Ig 11 M FTD bvFTD S 47 rs368220468
DR1225.1 p.L1364F Ig 12 F FTD PSP U 83 -
AD1788.1 p.R1370Q Ig 12 M FTD - S 68 -
DR867.1 p.A1551T Ig 14 M FTD bvFTD F 77 -
DR559.1 p.E1571K Ig 14 F FTD bvFTD F 60 - TREM2 p.R47H
DR1226.1 p.E1571K Ig 14 M FTD SD S 75 -
DR355.1 p.R1758W Linker Ig 15–16 F FTD bvFTD S 75 rs369187211
DR825.1 p.V2014A Ig 18 F FTD PNFA S 66 -
AD1462.1 p.T2025I Ig 18 F FTD PPA + EPS S 62 - GRN p.0(IVS1 + 5G > C)
DR1227.1 p.T2025I Ig 18 F CBS CBS U 70 -
DR868.1 p.R2318Q Ig 21 M FTD PNFA S 71 -
AD1321.1 p.S2461N Ig 22 F FTD - U 63 -
bvFTD behavioral variant frontotemporal dementia, CBD corticobasal degeneration, CBS corticobasal syndrome, dbSNP Single Nucleotide Polymorphism database, EPS
extrapyramidal syndromes, exp. expansion, F familial, GRN progranulin, PNFA progressive nonfluent aphasia, PPA primary progressive aphasia, PSP progressive
supranuclear palsy, S sporadic, TREM2 Triggering receptor expressed on myeloid cells 2, U family history undocumented
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increase in pSer2113 levels in GRN loss-of-function mu-
tation carriers. In contrast to total FLNC levels, VCP
mutation carriers also showed a strong increased phos-
phorylation of FLNC at position pSer2113. Surprisingly,
the FLNC p.V831I showed a lower degree of pSer2113
levels compared to the low frequency variant (p.R1241C)
carrier (Fig. 2b). Upregulation of phosphorylation of
FLNC pSer2213 could only be detected in GRN p.0(IVS1 +
5G >C) carriers and was not present in controls or other
FTD-related mutation carriers (Fig. 2b).
Elevated Flnc expression levels are confirmed in a
progranulin knockout mouse model
We aimed at validating the altered transcript profile present
in FTLD-TDP patients with GRN haploinsufficiency in
progranulin (Grn) knockout mice [24]. We analyzed ex-
pression levels of both long and short isoforms of
mouse Flnc in heterozygous Grn+/- and homozygous
Grn-/- transgenic mice compared to wild-type (Wt) ani-
mals at 3 months, 9 months, 16–18 months and 24 months
of age. Consistent with the data obtained for FTLD-TDP
patients with GRN haploinsufficiency, transcript levels of
both Flnc isoforms increased significantly in an age-
dependent manner in Grn-/- brains starting from an age of
16–18 months and increasing to a fivefold at 24 months of
age (P <0.0001) (Fig. 3a). No changes in Flnc isoform
expression were observed between heterozygous Grn+/-
and Wt mice up to an age of 24 months despite a small
age-related tendency to increase in relative values. Util-
izing a mouse Flnc-specific antibody, Flnc protein levels
Fig. 2 Analysis of FLNC expression in FTD patients at transcript and protein level. a qRT-PCR analysis showed significantly increased levels of both the short
and long isoform of FLNC in the frontal cortex of FTLD-TDP patients with GRN haploinsufficiency. The long isoform was also significantly increased in
FTLD-TDP patients without a known mutation in causal FTD-ALS genes. b Increased expression levels of FLNC were confirmed on protein level using
immunoblot analysis. In contrast to transcript levels, FLNC was also upregulated in VCP and FLNC variation carriers. Elevated phosphorylated FLNC levels at
serines 2113 and 2213 (pSer2113 and pSer2213) were identified to a variable extent in GRN and VCP mutation carriers compared to controls. *P<0.05; ***P<0.001
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were found to progressively increase with age and the
strongest increase was detected at an age of 21 months
in Grn-/- mice which is comparable to the transcript
data (Fig. 3b).
Further in line with the human data is that Flnc levels
remained unchanged in two mouse models of AD, includ-
ing Tg2576 mice overexpressing the Swedish APP variant
p.KM670/671NL (Taconic Farms Inc.) or T8B7 mice ex-
pressing the PSEN1 p.G384A mutation (Additional file 2:
Figure S2b) [50]. Due to the high sequence homology be-
tween Flnc and other members of the filamin family, we
also investigated the expression levels of filamin A (Flna,
≈72 % homology) and filamin B (Flnb, ≈70 % homology)
in our Grn-/- mouse model. No significant alterations were
identified for both Flna and Flnb transcripts at end-stage
Grn-/- mice compared to Wt mice (Additional file 2:
Figure S2c-d), suggesting that the identified alterations
are Flnc specific. Expression of other FTD-related genes,
e.g. Tdp-43,Vcp and C9orf72 in Grn-/- mice remained un-
altered as well (Additional file 2: Figure S2e-g).
Proteomic investigation of frontal cortex of FTD patients
with increased FLNC levels using iTRAQ
To investigate the post-genomic sequelae of the human
FLNC phenotype we performed an exploratory quantita-
tive proteomic study of the frontal cortex (BA10) from
patients carrying the FLNC p.V831I variant, the GRN
p.0(IVS1 + 5G > C) mutation and VCP p.R159H mutation
compared to control individuals. C9orf72 repeat expansion
carriers were not included due to the absence of a
Fig. 3 Analysis of Flnc expression in Grn knockout mice at transcript and protein level. qRT-PCR analysis of the long and short isoform of Flnc
(a) measured in progranulin knockout mice of different ages. We analyzed the expression levels of both long and short isoforms of mouse Flnc in
heterozygous Grn+/- and homozygous Grn-/- mice and wild-type (Wt) animals of 3 months (n = 4), 9 months (n = 4), 16-18 months (n = 6) and
24 months (n = 5) of age. b Increased FlnC expression levels were confirmed on protein level using quantitative immunoblot analysis. Two
protein bands are detected around the height of mouse FLNC using the Kinasource AB152 anti FLNC antibody. The upper band is FLNC specific as
determined by Western blotting using lysates from FlnC knockout mice (data not shown). The lower band is therefore considered as an
aspecific protein band. *P < 0.05; ***P < 0.001, n.s. not significant
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detectable FLNC increase. We found that 294, 326 and
337 proteins were significantly and differentially regu-
lated for FLNC (Additional file 1: Table S6), GRN
(Additional file 1: Table S7) and VCP (Additional file 1:
Table S8) patients, respectively. Venn diagram separation
of these significant protein datasets demonstrated the
presence of a core set of 71 common and coherently
regulated (with respect to elevated or reduced expres-
sion) proteins across all genomic FTD etiologies (Fig. 4a,
Additional file 1: Table S9). We validated phosphoglyc-
erate mutase 2 (PGAM2) and syntaxin binding protein
2 (STXBP2) via Western blot analysis (Fig. 4b), which
closely paralleled the quantitative mass spectrometry
data (exemplary iTRAQ reporter ion analysis for both
proteins is represented in Additional file 2: Figure S4a,b).
We also explored the nature of the proteins unique to
each FTD paradigm, i.e. specific to the FLNC (p.V831I),
GRN (p.0(IVS1 + 5G > C)) or VCP (p.R159H) patients
(Additional file 1: Table S10-12).
Differential bioinformatic interpretation of quantitative
proteomic analyses
To create a gestalt biomedical appreciation of the dif-
ferential expression datasets, we employed Textrous!
natural language processing (NLP) based analysis to gen-
erate a focussed semantic interpretation of the common
FTD dataset and the FLNC-, GRN- and VCP-unique
datasets. Using the Textrous! individual processing
module we found for the FTD-common protein data-
set the strongest correlations between the words ‘den-
drites’, ‘growth-associated’, ‘cytoskeleton’, ‘polymerization’,
and ‘synapses’ and following proteins: growth associ-
ated protein 43/neuromodulin (GAP43), glial fibrillary
acidic protein (GFAP), brain acid soluble protein 1
(BASP1), neuroplastin (NPTN) and neuronal pentraxin-1
(NPTX1) (Fig. 5a). To effectively condense the terms in-
volved in the individual processing matrix we extracted all
the semantically-associated nouns and noun-phrases
from this output to generate a higher-order word cloud
(Fig. 5b, Additional file 1: Table S13a), reinforcing the
strong cytoskeletal/dendritic/synaptic focus of the FTD-
common dataset.
We next focussed on a similar NLP-based interpretation
of the FLNC-specific protein dataset. Repeating the Tex-
trous! NLP analysis for the FLNC p.V831I variant (Fig. 6a),
as with the FTD-common dataset, we found strong cor-
relations between the words ‘neuronal-Wiskott–Aldrich
Syndrome protein (N-wasp)’, ‘cytoskeleton’, ‘neurites’, ‘mi-
crotubules’ and ‘filopodia’ and following proteins: CAP-
GLY domain containing linker protein 1 (CLIP1), Wiskott-
Aldrich syndrome protein family member 3 (WASF3),
Myc box-dependent-interacting protein 1 (BIN1) and
microtubule-associated protein 4 (MAP4). Interestingly,
and in contrast to the FTD-common dataset interpret-
ation, a strong neurodegenerative focus was also present in
the FLNC dataset interpretation, i.e. semantic association
with multiple disease-related words including ‘aggregations’,
‘oxidation’, ‘tangles’, ‘tauopathies’, ‘neurodegenerative’, ‘inclu-
sion’ and ‘frontotemporal’. This dual functionality of the
FLNC-unique dataset, i.e. cytoskeleton/neurodegeneration
was also strongly evident from the extracted higher-order
word cloud (Fig. 6b, Additional file 1: Table S13b). Hence
the FLNC proteomic phenotype appears closely focused
on neuroskeletal mechanisms tightly linked with neuro-
degenerative activity.
Fig. 4 Visualization and validation of FLNC proteomics datasets on
FTD patients. (a) Three-set Venn diagram separation of the significant
protein datasets obtained from proteomic analysis of FTD patients with
increased FLNC levels, i.e. FLNC p.V831I, GRN p.0(IVS1 + 5G > C) and VCP
p.R159H carriers. Proteins depicted in the Venn diagrams are either
up- (italic), down-(underlined) or contra-regulated (red) when compared
to expression levels of control individuals (n= 3). (b) Among the core of
most up- or downregulated proteins, phosphoglycerate mutase 2
(PGAM2) and syntaxin binding protein 2 (STXBP2) were validated
using Western blot analysis
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Using an identical NLP-based informatic approach for
the GRN- (Additional file 2: Figure S5a, b) and VCP-
unique (Additional file 2: Figure S6a, b) datasets we
found that the GRN dataset was focussed upon
‘transporter’, ‘mitochondrial’, ‘oxidation’ and ‘cellular mo-
tility’ activity while in contrast the VCP-unique dataset was
more focussed upon neuronal ‘synaptic’, ‘vesicle’, ‘transmis-
sion’ and ‘plasticity’ functions (Additional file 1: Table
Fig. 5 Representation of FTD-common protein dataset using Textrous! and word clouds. (a) Analysis of the FTD-common protein dataset using
Textrous! natural language processing (NLP). Strongest correlations between words (vertical) and proteins (horizontal) are presented in a Textrous!
heat map. Teal-colored blocks indicate strongly-associated geneword interactions in an intensity-sensitive manner; grey blocks indicate no
significant interaction. (b) Word clouds obtained from Wordle (http://www.wordle.net/) analyzing the Textrous! output data common to all FTD
patients
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S13c-d). A general overview of the top 10 highest fre-
quency words for each ‘higher-order’ word cloud, both
FTD-common and the individual unique datasets, are out-
lined together in Additional file 1: Table S13a-d.
Overall, it is evident that for the FLNC-, GRN- and
VCP-specific paradigms a specific and idiosyncratic post-
genomic FTD-related functionality is present. As we
found that the FLNC-unique protein dataset was strongly
Fig. 6 Representation of the FLNC p.V831I unique protein dataset using Textrous! and word clouds. (a) Analysis of the FLNC p.V831I unique
protein dataset using Textrous! natural language processing (NLP). Strongest correlations between words (vertical) and proteins (horizontal)
are presented in a Textrous! heat map. Teal-colored blocks indicate stronglyassociated gene-word interactions in an intensity-sensitive
manner; grey blocks indicate no significant interaction (b) Word clouds obtained from Wordle (http://www.wordle.net/) analyzing the
Textrous! output data unique for the FLNC p.V831I variant
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associated with a neurodegenerative/oxidative damage sig-
nature we attempted to independently quantify this using
an orthogonal informatic approach to Textrous!. Hence
we sought to evaluate the semantic correlation between
user-defined words associated with neurodegeneration,
dementia and aging and proteins from the FLNC-, GRN-
or VCP-specific datasets. This was performed using the
LSI-based GeneIndexer application. Through summation
of the total cosine similarity scores for the input interroga-
tor word terms and taking into account the relative sizes
of input datasets, we found that multiple factors in the
FLNC-specific protein dataset (Fig. 7) demonstrated the
strongest semantic correlations to multiple terms asso-
ciated with FTD (Additional file 1: Table S14-16). There-
fore it appears that, for the FLNC-FTD patients, both
protein and bioinformatic associations demonstrate a
relatively unique and profound connection to FTLD
pathology.
Discussion
Investigating the pathogenicity of TDP-43 deletion in
zebrafish by Schmid et al. [12] demonstrated a potential
role for muscle-specific proteins in the disease mechan-
ism underlying FTD-ALS disorders, with FLNC being
the most up-regulated protein. A potential link between
the loss of TDP-43 in zebrafish, and the concomitant al-
tered expression of FLNC, and the human disease was
provided by the observation of elevated FLNC levels in
the frontal cortex of FTLD-TDP patients. To further ex-
plore the potential involvement of FLNC in FTLD patho-
genesis, we consequently screened the Belgian FTD patient
and control cohorts for the presence of FLNC variants as-
sociated with FTD and determined the genetic etiology
underlying the elevated FLNC expression levels in FTLD-
TDP patients as observed by Schmid et al. [12]. Molecular
genetic screening of the coding sequence of FLNC resulted
in the identification of 68 missense variants, of which 19
were missense variants identified in 21 FTD patients only.
All variants reported in this study are rare (MAF <1 %), ex-
cept the p.R1241C and p.R1567Q missense variants which
were low frequency (1 % <MAF <5 %) and frequent
(MAF >5 %) variants, respectively. When considering
all rare variants, indifferent if they were present or not
in control individuals, FTD patients demonstrated a sig-
nificant enrichment of rare variants (cumulative variant
frequency of 11.3 %) when compared to control individ-
uals (cumulative variant frequency of 7.9 %) (P = 0.0349;
OR = 1.46, 95 % CI = 1.03–2.07).
Formerly, mutations in FLNC were described as an
underlying cause of two distinct types of myopathy, known
as myofibrillar and distal myopathy (MFM and DM) [17].
These myopathies are characterized by a progressive weak-
ening of either proximal (MFM) or distal (DM) skeletal
muscles combined with severe muscle defects [22, 23]. The
disease spectrum has recently been broadened by the iden-
tification of novel genetic alterations in FLNC in patients
with hypertrophic cardiomyopathy (HCM) [21]. Patients
with HCM have marked sarcomeric abnormalities in car-
diac muscles which cause an increased incidence of sudden
cardiac death [51].
Based on the currently available data, we can suggest
that the missense variants detected in FLNC are specific
to the FTD phenotype based on a number of reasons.
First, none of the FLNC variants identified in the Belgian
FTD cohort were previously reported as a causal factor
underlying any form of (cardio)myopathy. One exception
is p.A2430V which was identified in one Belgian control
individual, and had previously been reported in a pa-
tient with HCM [21]. In this latter study, however, the
p.A2430V variation was classified as neutral by the
SIFT prediciton software tool and considered a poten-
tial rare polymorphism in FLNC, which is supported by
our observation of the p.A2430V variant in a Belgian
control individual. Second, the FLNC carriers with FTD
in our study did not show overt clinical signs of any
form of myopathy. Considering that the average onset
age of most FTD patients is older than of myopathy pa-
tients further strengthens our interpretation that the
FLNC variants we observed are specific for FTD. Third,
the missense variations in FTD are affecting evolution-
ary conserved regions across the actin binding domain
(ABD) and the 24 Immunoglobulin (Ig)-like domains
(Fig. 1b, Additional file 2: Figure S1). Although the
pathogenicity of the FLNC variations remains speculative,
p.V831I and p.R1241C showed alterations in the expres-
sion of the FLNC protein itself or its phosphorylation
state. A number of FLNC variations - p.R81C, p.K524R,
p.D710N, p.R1241C, and p.T2025I - were identified in
Fig. 7 Total cosine similarity scores of the FLNC proteomics datasets
on FTD patients. Summation of the total cosine similarity scores for
the input interrogator terms showed that the FLNC-unique protein
dataset demonstrated the strongest semantic correlation to multiple
factors associated with FTD compared to the GRN or VCP-datasets.
Factors included in the analysis comprise frontotemporal, dementia,
neurodegeneration and aging. Calculations take into account the
relative sizes of input datasets
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FTD patients who carried a causal mutation in another
FTD gene i.e. FLNC p.R1241C in a VCP p.R159H carrier,
FLNC p.R81C and p.T2025I in GRN loss-of-function mu-
tation carriers [10], and FLNC p.K524R and p.D710N
in C9orf72 repeat expansion carriers [11] (Table 2,
Additional file 1: Table S3b). Co-occurrence of FLNC
variants with causal GRN or C9orf72 mutations is not
surprising since they are the most frequent mutations
found in FTD patients in Belgium. Also, FLNC p.E1571K
was identified in a FTD patient carrying the TREM2
p.R47H risk allele [52, 53]. Whether the presence of these
FLNC missense variations may influence the pathological
effect of causal mutations in C9orf72 or GRN, or exert an
additional pathological effect remains to be investigated.
Overall, our genetic data obtained suggested that the role
of FLNC variations might not be restricted to skeletal or
cardiac muscle disorders, but might also be modifying the
neurodegenerative processes in FTD patients. This implies
that variations found in the same or in different functional
domains of FLNC can be associated with distinct disease
phenotypes involving miscellaneous tissues. This can be
potentially explained by scaffolding functions of FLNC
where different variants in certain protein domains could
have differential effects on downstream signaling path-
ways or modulate distinct forms of FLNC protein-protein
interactions.
Besides the moderate increase of FLNC levels in the
frontal cortex of the FLNC p.V831I carrier, the GRN
p.0(IVS1 + 5G > C) loss-of-function and to a lower
extent the VCP p.R159H mutation showed a marked
up-regulation of total FLNC levels. The potential link
between GRN and FLNC was further supported by the
strong increase in mouse Flnc levels observed in the frontal
cortex of Grn-/- mice between 16-18 months and 24 months
of age. Hence it seems that in this FTD paradigm a strong
aging-dependent triggering process may be in evidence.
Interestingly, the VCP p.R159H seemed to have a
more pronounced effect on the phosphorylation state of
pSer2113 while this was more the case for pSer2213 in
GRN loss-of-function patients, suggesting that alterna-
tive pathways are affected in these patients. Increased
phosphorylation at pSer2113 and pSer2213 of FLNC, might
hamper the interaction of FLNC with other signaling pro-
teins or its ability to modulate downstream signal trans-
duction [49]. Further research, however, is required to
determine the downstream functional discrepancies be-
tween elevated levels of total FLNC and both phosphoryl-
ation states of FLNC.
How elevated FLNC levels in the brain can influence
the development of TDP-43 proteinopathies remains
unknown. Studies performed in cellular and animal
models, however, have demonstrated that a precise
stoichiometry of FLNC together with its associated
signaling/binding proteins is of critical importance for
muscle function and maintenance [54]. Furthermore, it
has been suggested that a certain threshold level of fila-
mins may be essential for cell viability [14, 55]. In non-
muscle cells, filamins are reported to colocalize along
stress fibers implicating that they might play a role in
maintaining focal adhesion complexes and stabilization
of cytoskeletal features [56]. As no changes in both
Flna and Flnb could be observed, the elevated levels of
FLNC identified both in human and in mouse could
hamper neuronal cellular integrity or axonal/dendritic
plasticity in the brain to cope with additional stressors
or alterations during degenerative and aging processes.
This posit is in line with the Flnc expression patterns
that we measured in the brains of Grn-/-mice. As men-
tioned previously, our expression data obtained from
aged Grn-/- mice demonstrated a strong increase of
Flnc in brain between 16-18 months and 24 months.
At an age of 23.5 months, the highest Flnc levels in
mice also correlate with an 17.5-fold higher relative risk
of dying for Grn-/- mice compared to Grn+/- mice [24].
This suggests that elevated Flnc levels might play an im-
portant role in mediating or accelerating the pathological
aging process.
A potential role for accelerated aging and neurode-
generation, due to increased FLNC levels, is further sup-
ported by the identification of several protein factors in all
differential datasets obtained from our exploratory quanti-
tative proteomic analyses on the frontal cortex of a se-
lected number of FTD patients with different genetic
etiologies. For example, low levels of neurogranin show a
clear correlation with cognitive deficits and aging [57].
The key role played by neuroplastins in synapse formation
and its association with impaired intellectual ability might
be indicative for the role of FLNC [58]. Furthermore, we
identified also increased PGAM2 expression levels in the
FLNC- and GRN-unique datasets as an additional muscle-
specific protein that shows altered expression levels in the
brain. Interestingly, PGAM2 overexpression has previ-
ously been associated with an altered energy metabolism
and reduced stress resistance due to a decreased respir-
ation capacity in mitochondria and increased production
of reactive oxygen species in the heart of Pgam2 overex-
pression mice [59]. Abnormal energy metabolism has re-
cently been linked to inflammation [60]. Furthermore,
additional proteins which were consistently altered in both
the FLNC-, GRN- and VCP-unique datasets, e.g. GFAP
[61], NPTN [62], DBI [63], PRDX6 [64], MARCKS [65]
and BSN [66], are closely associated with cognitive func-
tion, dementia and pathological aging, (Additional file 1:
Table S6-8). Altered expression levels in these proteins
could explain the observed accelerated aging of Grn-/-
mice and concomitant increase in Flnc, but clearly further
research into this aging-neurodegenerative nexus in FTD
is necessary.
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Compared to the GRN- and VCP-unique datasets, the
FLNC-unique protein dataset showed the strongest cor-
relation to frontotemporal dementia, neurodegeneration
and aging (Figs. 6 and 7). The bioinformatic analyses of
all differential datasets provided evidence that the FLNC-
unique protein dataset showed the greatest similarity to
the core functions of the FTD-common protein dataset
with respect to the modulation of neuronal structure or
cytoskeletal dynamics (Figs. 5 and 6). Further support for
the strong and specific connection between the core FTD
functionality and the FLNC-specific dataset was provided
by the application of standard bioinformatic investigations
with GO Term and KEGG pathway analyses (Additional
file 1: Table S17-20). The results of our exploratory prote-
omic analyses of frontal cortex of FTD patients are en-
couraging the involvement of FLNC in FTD disease
pathways, however, further experiments are required to
confirm these observations and should be extended on
potential brain material of additional FTD patients with
concomitant elevated FLNC levels.
Hence we found four common significantly populated
GO terms between the FTD-common and FLNC-specific
dataset, i.e. oxidative phosphorylation, generation of
precursor metabolites and energy, cellular protein complex
assembly and protein polymerization. Only one common
GO term could be found between the GRN-unique
(transmembrane transport) or VCP-unique (ribonucleo-
tide metabolic process) datasets and the FTD-common
dataset. At the KEGG pathway level, four common
pathways were identified between the FTD-common and
the FLNC-unique dataset: oxidative phosphorylation,
Parkinson's disease, Alzheimer's disease, pathogenic
Escherichia coli infection. No common pathways were
found between the GRN- or VCP-unique datasets and the
FTD-common dataset. In both cases the bioinformatic
interpretation of the FLNC-unique dataset reveals a
strong neurometabolic, neuronal architectural and neu-
ordegenerative functional bias.
Conclusions
The data presented here provide further support that
FLNC, a muscle-specific protein, could be a potential novel
player in FTD pathogenesis. More specifically, we report a
significant association between rare variants in FLNC and
FTD. We have demonstrated that elevated FLNC levels in
the frontal cortex of FTD patients are mainly associated
with GRN haploinsufficiency and to a lower extent to the
FLNC p.V831I and VCP p.R159H mutation. The GRN as-
sociated increase of FLNC was confirmed in the frontal
cortex of aged Grn knockout mice. Moreover, proteomic
analysis of FTD patients with increased FLNC levels points
towards downstream alterations in pathways involved in
aging, neurodegeneration and synaptogenesis, suggesting
that FLNC levels might have a potential role in mediating
or accelerating the aging process. However, the exact mode
of action of increased FLNC levels in the brain of FTD
patients is currently unknown and requires further
investigation.
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